Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-5849

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 50090-5849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure diagram of Bisoprolol Fumarate and Hydrochlorothiazide showing molecular connectivity and functional groups.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure diagram of Bisoprolol Fumarate, showing atomic connections and functional groups clearly associated with this active ingredient.*
FDA Label Image

Label Image (Lbl500905849)

Label Image (Lbl500905849)
Label for Bisoprolol Fumarate and Hydrochlorothiazide 5 mg/6.25 mg film-coated tablets, manufactured by A-S Medication Solutions. The label includes storage instructions to keep at 68 to 77 degrees Fahrenheit and states the package contains 30 tablets. The product NDC is 50090-5849.*
FDA Label Image

Table 1 (Table 1 New)

Table 1 (Table 1 New)
A data table presenting the mean decreases in sitting systolic/diastolic blood pressure (BP) and heart rate (HR) after 3-4 weeks from two studies. The table compares placebo and different doses of Bisoprolol Fumarate and Hydrochlorothiazide combinations, showing changes in BP and HR, with drug effects calculated as mean changes from baseline minus placebo.*
FDA Label Image

Table-3 (Table 3 New)

Table-3 (Table 3 New)
A data table presenting the percentage of patients with various adverse experiences, categorized by body system and specific adverse events, comparing placebo versus Bisoprolol Fumarate and Hydrochlorothiazide (B2.5-40/H6.25) groups. It shows both all adverse experiences and drug-related adverse experiences across cardiovascular, respiratory, body as a whole, central nervous system, musculoskeletal, psychiatric, and gastrointestinal categories.*
FDA Label Image

Table-2 (Table New 2)

Table-2 (Table New 2)
A data table titled 'Serum Potassium Data from U.S. Placebo Controlled Studies' comparing potassium levels for Placebo and various doses of Bisoprolol Fumarate and Hydrochlorothiazide (B2.5/H6.25 mg, B5/H6.25 mg, B10/H6.25 mg, and B10/H25 mg). It includes mean change in potassium (mEq/L) and incidence of hypokalemia for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.